The story of the European Randomized Study of Screening for Prostate Cancer.
about
Screening for prostate cancerScreening for prostate cancerKi-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App.Quality-of-life effects of prostate-specific antigen screening.Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.Complications of initial prostate biopsy in a European randomized screening trialActive surveillance for prostate cancer: a legal perspectiveProstate-specific antigen-based screening: controversy and guidelinesWhat do the screening trials really tell us and where do we go from here?The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.Prostate cancer: net survival and cause-specific survival rates after multiple imputation.Technical considerations when obtaining and interpreting prostatic biopsies from men with suspicion of early prostate cancer: part I.The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk.The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers.Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.The implementation of screening for prostate cancer.Screening for prostate cancer: a controversy or fact.Risk stratification in prostate cancer screening.Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges.A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analoguesEffects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC).Education concerning carcinoma of prostate and its early detection.Non-prostatic pathology on prostate needle-biopsy - colorectal carcinoid: a case reportLong-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer.Screening for prostate cancer in younger men.Excess all-cause mortality in the evaluation of a screening trial to account for selective participation.Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men.Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality.Identifying and characterizing "escapes"-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam).Do additional cores from cancer-suspicious lesions on transrectal ultrasound improve prostate cancer detection including index tumors over 12-core systematic biopsy?Recent trends in prostate cancer mortality show a continuous decrease in several countries
P2860
Q24201690-3BE5D8B9-12BD-4E17-B584-330C1861E259Q24245476-0F09B168-DFF1-4A08-96F5-5FFCC96347FFQ33379156-2FAB5EFF-B41B-49E0-8585-AEEEF4AF9D57Q33454007-47F0AA37-1212-4C3F-B112-A0DBCA127780Q34294102-AF141CA1-62E8-4DD8-B20E-D81DE8A0257DQ34294898-09F37832-E6D8-4605-BB0D-64B3CE63DD16Q34448107-DDB2DB9F-8F58-4B24-B7D9-814BC17920D1Q34978724-3DE5345D-5C53-4058-9299-005138909EE5Q35211931-C2DE4197-E45D-460F-BCB7-D935725C4B0EQ35234770-12E36CC2-667F-4854-86B5-81279A31D2FCQ35532150-36034B6B-0817-4CF3-92ED-905A0543B250Q35717806-5A56FD3D-BDF5-4669-AE7D-F965ACAA750FQ36118574-7B405B9F-7177-438F-B890-C8E1EB8B0475Q36613795-845302B1-2BEE-464B-8ED4-14B8066EC4C3Q36837289-930D1DD0-2633-451E-9170-527D894407D2Q37039297-162B02C4-AC8C-4B8C-9166-BC096783FF99Q37171140-BFC9417F-397B-48D5-819F-CA431DF93423Q37430370-382BDD5E-B1B6-4E6B-A9CC-CB61449D62C2Q37777325-69812D36-DCBE-45D8-B9BE-FBB175DE42D0Q37803538-515A8ED4-43D9-4A02-B570-4ED870670ECEQ38068114-31943212-5319-492D-815E-254A1E426AE4Q38092015-40A72B35-B6BF-4429-8FB2-312F1711142BQ39735399-CDF9AAF3-5962-4CD4-8CA0-722B83759689Q40118979-4D746E1A-FCD1-48D0-84B9-2C311C87F7FCQ41948649-D4BB1BC4-628A-4DD0-A321-5EA150F0127DQ42006813-8721F29A-8713-48E4-A082-472D06C5C96DQ42287916-FB3A3AB5-09EA-4806-90EF-B5B6A183C5B9Q42738525-D3EB330C-CA38-44FE-9ABF-0F3432C3D11AQ44104451-E80EB41A-BD7E-4349-B8A3-C34575DD9F91Q46465755-98367AA0-62AE-47D2-8EF5-6982C3527E07Q48367260-DFCC4E8E-7B4A-4BCD-B3E8-830E4107ACE0Q51584281-877B7A74-81BD-4D42-AA01-335DB8EB6170Q55313673-89231CC3-034A-4301-AD4C-26D94ED1A4A0Q57211499-CE5116FB-BE57-444F-B475-BBD779C1FFDD
P2860
The story of the European Randomized Study of Screening for Prostate Cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The story of the European Randomized Study of Screening for Prostate Cancer.
@ast
The story of the European Randomized Study of Screening for Prostate Cancer.
@en
type
label
The story of the European Randomized Study of Screening for Prostate Cancer.
@ast
The story of the European Randomized Study of Screening for Prostate Cancer.
@en
prefLabel
The story of the European Randomized Study of Screening for Prostate Cancer.
@ast
The story of the European Randomized Study of Screening for Prostate Cancer.
@en
P2093
P2860
P1433
P1476
The story of the European Randomized Study of Screening for Prostate Cancer.
@en
P2093
A Berenguer
F H Schröder
J Hugosson
M Kwiatkowski
P2860
P356
10.1111/J.1464-410X.2003.04389.X
P478
92 Suppl 2
P577
2003-12-01T00:00:00Z